TD Asset Management Inc Cuts Stock Holdings in Prestige Consumer Healthcare Inc. $PBH

TD Asset Management Inc reduced its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 33.6% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 18,600 shares of the company’s stock after selling 9,400 shares during the period. TD Asset Management Inc’s holdings in Prestige Consumer Healthcare were worth $1,485,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Cerity Partners LLC grew its stake in shares of Prestige Consumer Healthcare by 3.7% in the 1st quarter. Cerity Partners LLC now owns 3,666 shares of the company’s stock worth $315,000 after buying an additional 132 shares in the last quarter. UMB Bank n.a. grew its stake in shares of Prestige Consumer Healthcare by 81.8% in the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after buying an additional 144 shares in the last quarter. KBC Group NV grew its stake in shares of Prestige Consumer Healthcare by 7.4% in the 1st quarter. KBC Group NV now owns 2,199 shares of the company’s stock worth $189,000 after buying an additional 151 shares in the last quarter. Xponance Inc. grew its stake in shares of Prestige Consumer Healthcare by 5.5% in the 1st quarter. Xponance Inc. now owns 3,766 shares of the company’s stock worth $324,000 after buying an additional 196 shares in the last quarter. Finally, Resona Asset Management Co. Ltd. grew its stake in shares of Prestige Consumer Healthcare by 2.3% in the 1st quarter. Resona Asset Management Co. Ltd. now owns 9,105 shares of the company’s stock worth $783,000 after buying an additional 203 shares in the last quarter. 99.95% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on PBH shares. Weiss Ratings reissued a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Zacks Research cut shares of Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a research note on Thursday, September 4th. Canaccord Genuity Group dropped their price objective on shares of Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Sidoti raised shares of Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target for the company in a research note on Wednesday, September 24th. Finally, Oppenheimer dropped their price target on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating for the company in a research note on Tuesday. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $90.60.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $63.37 on Thursday. Prestige Consumer Healthcare Inc. has a 12 month low of $60.15 and a 12 month high of $90.04. The company has a current ratio of 4.38, a quick ratio of 2.99 and a debt-to-equity ratio of 0.55. The company has a 50-day moving average price of $64.16 and a 200 day moving average price of $74.93. The stock has a market cap of $3.12 billion, a PE ratio of 14.87, a P/E/G ratio of 1.98 and a beta of 0.44.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, August 7th. The company reported $0.95 EPS for the quarter, missing analysts’ consensus estimates of $1.01 by ($0.06). The firm had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.Prestige Consumer Healthcare’s revenue for the quarter was down 6.6% on a year-over-year basis. During the same period in the prior year, the firm posted $0.90 earnings per share. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS. Equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.